Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wunderink

Showing results (471-480 of 545) with videos related to

Pageof 55
Sort By:
American Journal of Respiratory and Critical Care Medicine|February 8, 2011
Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trialRichard G Wunderink, Pierre-François Laterre, Bruno Francois, et al.
Open Forum Infectious Diseases|May 9, 2017
Oseltamivir Use Among Children and Adults Hospitalized With Community-Acquired PneumoniaIkwo K Oboho, Anna Bramley, Lyn Finelli, et al.
Antimicrobial Agents and Chemotherapy|November 10, 2020
Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN)Thomas P Lodise, Scott Van Wart, Zoe M Sund, et al.
Pediatrics|October 1, 2016
Predicting Severe Pneumonia Outcomes in ChildrenDerek J Williams, Yuwei Zhu, Carlos G Grijalva, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 11, 2016
Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and OutcomesWesley H Self, Richard G Wunderink, Derek J Williams, et al.
American Journal of Respiratory and Critical Care Medicine|April 30, 2021
Nucleic Acid-based Testing for Noninfluenza Viral Pathogens in Adults with Suspected Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice GuidelineScott E Evans, Ann L Jennerich, Marwan M Azar, et al.
Chest|April 25, 2016
Procalcitonin as an Early Marker of the Need for Invasive Respiratory or Vasopressor Support in Adults With Community-Acquired PneumoniaWesley H Self, Carlos G Grijalva, Derek J Williams, et al.
Geroscience|September 7, 2024
Impact of healthcare system strain on the implementation of ICU sedation practices and encephalopathy burden during the early COVID-19 pandemicJeffrey R Clark, Ayush Batra, Robert A Tessier, et al.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
Longitudinal clinical proteomics reveals pneumonia type-specific protein biomarkers and autoantibodiesAnna Semenova, Taylor A Poor, Johannes B Müller-Reif, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 14, 2020
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)Ivan Titov, Richard G Wunderink, Antoine Roquilly, et al.
Pageof 55

Showing results (471-480 of 545) with videos related to

Sort By:
Pageof 55
American Journal of Respiratory and Critical Care Medicine|February 8, 2011
Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trialRichard G Wunderink, Pierre-François Laterre, Bruno Francois, et al.
Open Forum Infectious Diseases|May 9, 2017
Oseltamivir Use Among Children and Adults Hospitalized With Community-Acquired PneumoniaIkwo K Oboho, Anna Bramley, Lyn Finelli, et al.
Antimicrobial Agents and Chemotherapy|November 10, 2020
Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN)Thomas P Lodise, Scott Van Wart, Zoe M Sund, et al.
Pediatrics|October 1, 2016
Predicting Severe Pneumonia Outcomes in ChildrenDerek J Williams, Yuwei Zhu, Carlos G Grijalva, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 11, 2016
Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and OutcomesWesley H Self, Richard G Wunderink, Derek J Williams, et al.
American Journal of Respiratory and Critical Care Medicine|April 30, 2021
Nucleic Acid-based Testing for Noninfluenza Viral Pathogens in Adults with Suspected Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice GuidelineScott E Evans, Ann L Jennerich, Marwan M Azar, et al.
Chest|April 25, 2016
Procalcitonin as an Early Marker of the Need for Invasive Respiratory or Vasopressor Support in Adults With Community-Acquired PneumoniaWesley H Self, Carlos G Grijalva, Derek J Williams, et al.
Geroscience|September 7, 2024
Impact of healthcare system strain on the implementation of ICU sedation practices and encephalopathy burden during the early COVID-19 pandemicJeffrey R Clark, Ayush Batra, Robert A Tessier, et al.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
Longitudinal clinical proteomics reveals pneumonia type-specific protein biomarkers and autoantibodiesAnna Semenova, Taylor A Poor, Johannes B Müller-Reif, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 14, 2020
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)Ivan Titov, Richard G Wunderink, Antoine Roquilly, et al.
Pageof 55